國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格圖中華醫(yī)學(xué)雜志英文版課件

1、國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 1 國外和國內(nèi)國外和國內(nèi) 醫(yī)學(xué)期刊的醫(yī)學(xué)期刊的 不同之處不同之處 照日格圖照日格圖 中華醫(yī)學(xué)雜志英文版中華醫(yī)學(xué)雜志英文版(Chin Med J) 總編輯總編輯 中國醫(yī)學(xué)論壇報 理事會理事、顧問、前總編輯 美國新英格蘭醫(yī)學(xué)雜志美國新英格蘭醫(yī)學(xué)雜志(N Engl J Med) 編委編委 中華兒科雜志中華兒科雜志 副總編輯副總編輯 歐洲臨床研究雜志歐洲臨床研究雜志(Eur J Clin Invest) 編委編委 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 2 國外的和國內(nèi)的醫(yī)學(xué)期刊有許多不同國外的和國內(nèi)的醫(yī)學(xué)期刊有許多不同 國外

2、不少期刊歷史長、經(jīng)驗(yàn)豐富、辦刊質(zhì)國外不少期刊歷史長、經(jīng)驗(yàn)豐富、辦刊質(zhì) 量高、刊登高質(zhì)量高水平醫(yī)學(xué)論文多、及量高、刊登高質(zhì)量高水平醫(yī)學(xué)論文多、及 時反映醫(yī)學(xué)科學(xué)研究的進(jìn)展、收錄到國際時反映醫(yī)學(xué)科學(xué)研究的進(jìn)展、收錄到國際 大型科學(xué)文獻(xiàn)數(shù)據(jù)庫的多、高影響因子的大型科學(xué)文獻(xiàn)數(shù)據(jù)庫的多、高影響因子的 期刊多。期刊多。 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 3 刊名創(chuàng)刊年 N Engl J Med1812 Lancet1823 BMJ1840 JAMA1883 Arch Intern Med1908 Ann Intern Med1927 Chest 1935 Chin Med J 18

3、87 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 4 國外，特別是西方國家，以及澳大利亞、新國外，特別是西方國家，以及澳大利亞、新 西蘭和日本的醫(yī)學(xué)期刊，收錄到西蘭和日本的醫(yī)學(xué)期刊，收錄到SCI和和 Medline等大型數(shù)據(jù)庫的很多。我國醫(yī)學(xué)期刊，等大型數(shù)據(jù)庫的很多。我國醫(yī)學(xué)期刊， 近幾年已有近幾年已有20余部被余部被SCI收錄。收錄。2007年我國年我國 (包括港澳包括港澳)收錄到收錄到Medline的期刊的期刊87部。部。 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 5 收錄到收錄到SCISCI的我國內(nèi)地醫(yī)學(xué)及的我國內(nèi)地醫(yī)學(xué)及 相關(guān)學(xué)科期刊相關(guān)學(xué)科期刊( (原有

4、原有) ) Journal Titles Impact factor Journal Titles Impact factor Chinese Medical Journal (中華醫(yī)學(xué)雜志中華醫(yī)學(xué)雜志 英文版英文版) 0.858 Acta Pharmacol Sin (中國藥理學(xué)報中國藥理學(xué)報) 1.397 Cell Res (細(xì)胞研究細(xì)胞研究) 3.426 Acta Biochim Biophys Sin (中國生物化學(xué)生物物理學(xué)報中國生物化學(xué)生物物理學(xué)報) 0.931 Asian J Androl (亞洲男性學(xué)亞洲男性學(xué)) 1.737 Fungal Diversity (真菌多樣性真菌多

5、樣性) 2.297 Science in China Series C, Life Sciences 0.533 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 6 收錄到收錄到SCISCI的我國內(nèi)地醫(yī)學(xué)及的我國內(nèi)地醫(yī)學(xué)及 相關(guān)學(xué)科期刊相關(guān)學(xué)科期刊( (新增，臨床醫(yī)學(xué)新增，臨床醫(yī)學(xué)) ) 2.092 0.365 0.524 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 7 收錄到收錄到SCISCI的我國內(nèi)地醫(yī)學(xué)及的我國內(nèi)地醫(yī)學(xué)及 相關(guān)學(xué)科期刊相關(guān)學(xué)科期刊( (新增，基礎(chǔ)和綜合新增，基礎(chǔ)和綜合) ) 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 8 審稿方面的不

6、同審稿方面的不同 國外很多期刊對審稿工作和審稿人的要求國外很多期刊對審稿工作和審稿人的要求 很高、很嚴(yán)格。很高、很嚴(yán)格。 要求作到：公平、公正、嚴(yán)格遵守時間要要求作到：公平、公正、嚴(yán)格遵守時間要 求，保密，有高度負(fù)責(zé)的精神，認(rèn)真進(jìn)行審稿。求，保密，有高度負(fù)責(zé)的精神，認(rèn)真進(jìn)行審稿。 有利益沖突時及時向編輯部聲明，放棄審有利益沖突時及時向編輯部聲明，放棄審 閱稿件。閱稿件。 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 9 審稿的方式審稿的方式 盲化盲化 單盲單盲 ( (目前比較多見目前比較多見) ) 雙盲雙盲 完全公開完全公開 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版

7、 10 對稿件的總體評價對稿件的總體評價( (打分打分) ) 有些期刊請審稿人對稿件的創(chuàng)新性、科學(xué)性、有些期刊請審稿人對稿件的創(chuàng)新性、科學(xué)性、 實(shí)用價值等方面用評分的方法作出評價。實(shí)用價值等方面用評分的方法作出評價。 多數(shù)期刊要求審稿人在寫審稿意見時，給編多數(shù)期刊要求審稿人在寫審稿意見時，給編 輯部和作者輯部和作者分別分別寫出參考意見，不能混淆。不能寫出參考意見，不能混淆。不能 將給編輯的意見，特別是關(guān)于稿件取舍的意見，將給編輯的意見，特別是關(guān)于稿件取舍的意見， 寫入給作者的意見框內(nèi)寫入給作者的意見框內(nèi)( (國內(nèi)有些審稿人常這樣作，國內(nèi)有些審稿人常這樣作， 這不妥這不妥) )。 國外和國內(nèi)醫(yī)學(xué)

8、期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 11 審稿意見：審稿意見： 多數(shù)審稿人的審稿意見十分詳細(xì)、具體。這些都多數(shù)審稿人的審稿意見十分詳細(xì)、具體。這些都 對作者以及其他有關(guān)人員有重要的參考價值。對作者以及其他有關(guān)人員有重要的參考價值。 一般國外期刊的審稿意見由以下部分組成：一般國外期刊的審稿意見由以下部分組成： 1 1、對研究內(nèi)容的概括，即主要目的和主要結(jié)果、對研究內(nèi)容的概括，即主要目的和主要結(jié)果 2 2、研究的選題、設(shè)計，或其他方面的主要問題、研究的選題、設(shè)計，或其他方面的主要問題 3 3、文章的結(jié)構(gòu)、表述、語言等方面存在的問題、文章的結(jié)構(gòu)、表述、語言等方面存在的問題 4 4、對稿件的處

9、理意見、對稿件的處理意見 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 12 Reviewer: 1 In this article, the authors present the data on a randomized but not blinded study of oseltamivir, a Chinese herbal combination (CHC), a combination of the two, or placebo in treatment of . The authors found similar clinical outcomes with ose

10、ltamivir or the CHC compared to placebo but no benefit of the combination. Despite the fact that this is both an interesting finding and a novel approach, there are significant challenges that must be addressed by the authors - either by providing additional details or by discussing why they were no

11、t done. Specifically: 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 13 1. Introduction - some detail about the CHC needs to be included as well as some background data - why was this combination of herbs picked over others (esp since the authors cite other studies of other combinations later)? 2. Methods: A. There w

12、ere a lot of sites involved - was one IRB approval sufficient? B. How, specifically, was the CHC prepared - how was the solution standardized so that there were comparable amounts of active compounds in each dose? C. Why were the individuals hospitalized? This is not typical for influenza studies in

13、 high school students with mild disease? 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 14 D. How were symptom scores and symptom alleviation defined? Since one of the most important endpoints is symptom alleviation, why was this only done at discharge instead of when the patients felt better? E. Was no virology, oth

14、er than initial swabbing, performed? Virologic outcomes are a critical component and failure to assess this significantly limits the value of this study. F. I am surprised that you had such a round number for two different sample size calculations. G. Symptom score is not standardized and definition

15、s are also not consistent with prior flu studies making comparisons challenging. 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 15 3. Results - theres little more than what is presented in the abstract - more - including details about changes in symptom scores over time; clearly virology is needed as well. 4. Discuss

16、ion: A. Need to discuss better how this compound was picked and why the simpler compound wasnt assessed? What is felt to be the active ingredient? Are there studies planned to define this? B. Since the CHC functions with several proposed mechanisms, why do the authors hypothesize that there was no b

17、enefit to the combination? C. There are far more limitations than are listed 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 16 Reviewer: 2Reviewer: 2 SummarySummary 1. Double-blind method is not used, although it was 1. Double-blind method is not used, although it was randomized controlled trial.randomized controlled

18、 trial. 2. Combination therapy of oseltamivir and other 2. Combination therapy of oseltamivir and other CNS stimulating drugs is potentially harmful and is CNS stimulating drugs is potentially harmful and is not recommended as routine therapy for influenza not recommended as routine therapy for infl

19、uenza especially otherwise healthy teenagers.especially otherwise healthy teenagers. 3. It is difficult to understand the reasons why you 3. It is difficult to understand the reasons why you included patients who presented more than 48 included patients who presented more than 48 hours (but within 7

20、2 hours) after the onset of hours (but within 72 hours) after the onset of symptoms.symptoms. 4. Efficacy primary end point (time to resolution of 4. Efficacy primary end point (time to resolution of fever) is not appropriate to evaluate the efficacy of fever) is not appropriate to evaluate the effi

21、cacy of oseltamivir.oseltamivir. 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 17 5. Medication information other than the study drugs was not available except for acetaminophen and antibiotics. Especially NSAIDs and cough medicines affect the outcome but were not described. 6. there seems some bias in the degree of

22、 fever and time from onset of illness to intervention 7. However, proportion of participants with complete recovery at discharge was not significantly different in each study group compared control group. 8. Moreover that of M-MXSGT group (62.4%) is rather lower than control group (69.6%). 9. Report

23、ed adverse events are extremely few. Is it the real figure? 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 18 Details 1. Double-blind method is not used, although it was randomized controlled trial. This is stated in your discussion in the manuscript. Further explanation may be unnecessary. 2. Combination therapy of

24、oseltamivir and other CNS stimulating drugs is potentially harmful and is not recommended as routine therapy for influenza especially otherwise healthy teenagers. Teenagers are thought susceptible to serious abnormal behaviours leading to accidents even with fatal outcome1. . Other neuropsychiatric

25、adverse reactions to oseltamivir including sudden death especially during sleep are reported 1. 1) Hama R.2008b Fatal neuropsychiatric adverse reactions to oseltamivir: case series and overview of causal relationship. Int J Risk Safety Med: 20: 5-36 11 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 19 Several animal

26、experiments are also suggesting the Several animal experiments are also suggesting the causality, especially used in combination with CNS-causality, especially used in combination with CNS- stimulant such as ephedrine 2, 3 (main ingredient of M-stimulant such as ephedrine 2, 3 (main ingredient of M-

27、 MXSGT is ephedra which is the mixture of ephedrine like MXSGT is ephedra which is the mixture of ephedrine like substances).substances). 2) Izumi Y, Tokuda K, Odell KA, Zorumski CF, Narahashi 2) Izumi Y, Tokuda K, Odell KA, Zorumski CF, Narahashi T. 2007. NeuroexcitatoryT. 2007. Neuroexcitatory act

28、ions of Tamiflu and its carboxylate metabolite. actions of Tamiflu and its carboxylate metabolite. Neurosci Lett. 426(1):54-8.Neurosci Lett. 426(1):54-8. Epub 2007 Sep 1. Epub 2007 Sep 1. 3) Izumi Y, Tokuda K, ODell K, Zorumski C, Narahashi T. 3) Izumi Y, Tokuda K, ODell K, Zorumski C, Narahashi T.

29、2008. Synaptic and2008. Synaptic and behavioral interactions of oseltamivir (Tamiflu) with behavioral interactions of oseltamivir (Tamiflu) with neurostimulants.neurostimulants. Hum Exp Toxicol. 27(12):911-7. Hum Exp Toxicol. 27(12):911-7. 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 20 3. The reason why you includ

30、ed patients who 3. The reason why you included patients who presented more than 48 hours (but within 72 hours) presented more than 48 hours (but within 72 hours) after the onset of symptoms is not understandable.after the onset of symptoms is not understandable. There has been no proof based on the

31、randomized There has been no proof based on the randomized controlled trials that show the efficacy in reducing controlled trials that show the efficacy in reducing time to resolution of symptoms by oseltamivir if it time to resolution of symptoms by oseltamivir if it is given after more than 48 hou

32、rs from the onset is given after more than 48 hours from the onset of symptoms. So if they include those presented of symptoms. So if they include those presented more than 48 hours after the onset of flu more than 48 hours after the onset of flu symptoms and claim the treatment efficacy of symptoms

33、 and claim the treatment efficacy of oseltamivir, it is misleading.oseltamivir, it is misleading. 4. Efficacy primary end point (time to resolution of 4. Efficacy primary end point (time to resolution of fever) is not appropriate to evaluate the efficacy fever) is not appropriate to evaluate the eff

34、icacy of oseltamivir.of oseltamivir. 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 21 Because unchanged oseltamivir that easily enter the brain Because unchanged oseltamivir that easily enter the brain through blood brain-barrier (BBB) and has CNS depressing through blood brain-barrier (BBB) and has CNS depressing a

35、ction which lower body temperature 3, 4, decreased time action which lower body temperature 3, 4, decreased time to resolution of fever could easily proved without true to resolution of fever could easily proved without true efficacy against flu.efficacy against flu. 4) Ono H, Nagano Y, Matsunami N,

36、 Sugiyama S, 4) Ono H, Nagano Y, Matsunami N, Sugiyama S, Yamamoto S, Tanabe M.2008.Yamamoto S, Tanabe M.2008. Oseltamivir, an anti-influenza virus drug, produces Oseltamivir, an anti-influenza virus drug, produces hypothermia in mice.hypothermia in mice. Biol Pharm Bull. 31(4):638-42. Biol Pharm Bu

37、ll. 31(4):638-42. 5. Medication information other than the study drugs was 5. Medication information other than the study drugs was not available except acetaminophen and antibiotics. not available except acetaminophen and antibiotics. Especially NSAIDs and medicines for the improvement of Especiall

38、y NSAIDs and medicines for the improvement of cough affect the outcome 4, 5 but were not described.cough affect the outcome 4, 5 but were not described. 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 22 M-MXSGT has antipyretic action like NSAIDs. it means in M-MXSGT has antipyretic action like NSAIDs. it means in the

39、 acute phase it decreased body temperature but in the the acute phase it decreased body temperature but in the later phase, it disturb the recovery of flu symptoms. This later phase, it disturb the recovery of flu symptoms. This adverse effect may explain lower tendency in proportion adverse effect

40、may explain lower tendency in proportion of full recovery in the M-MXSGT arm, though the fever of full recovery in the M-MXSGT arm, though the fever resolution was faster than control arm.resolution was faster than control arm. 5) Hama R. A/H1N1 flu. NSAIDs and flu. BMJ. 2009 Jun 5) Hama R. A/H1N1 f

41、lu. NSAIDs and flu. BMJ. 2009 Jun 15;338:b2345. doi: 10.1136/bmj.b2345.15;338:b2345. doi: 10.1136/bmj.b2345. 6. There seems some bias in the degree of fever and time 6. There seems some bias in the degree of fever and time from onset of illness to interventionfrom onset of illness to intervention a)

42、 Degree of fever: rather lower in control group: per cent a) Degree of fever: rather lower in control group: per cent of 39 C: 14.0 % in control arm vs 23.5 % in oseltamivir of 39 C: 14.0 % in control arm vs 23.5 % in oseltamivir arm, 21,4 % in M-MXSGT arm and 24.5 % in combination arm, 21,4 % in M-

43、MXSGT arm and 24.5 % in combination arm. Flu patients with high fever tend to recover faster arm. Flu patients with high fever tend to recover faster than those with low fever.than those with low fever. 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 23 b) Time from onset of illness to intervention: rather b) Time fro

44、m onset of illness to intervention: rather shorter in control arm (30 hours) than in the study arms shorter in control arm (30 hours) than in the study arms (35, 35, 32 respectively).(35, 35, 32 respectively). late presenting may recover earlier, so the baseline factor late presenting may recover ea

45、rlier, so the baseline factor is more favorable in the study arms than the control arm.is more favorable in the study arms than the control arm. 7. However, proportion of participants with complete 7. However, proportion of participants with complete recovery at discharge was not significantly diffe

46、rent in recovery at discharge was not significantly different in each study group compared control group.each study group compared control group. Proportions of complete recovery were 69.6 %, 72.5 %, Proportions of complete recovery were 69.6 %, 72.5 %, 62.1 and 70.6 % respectively.62.1 and 70.6 % r

47、espectively. 8. Moreover that of M-MXSGT group (62.4%) is rather lower 8. Moreover that of M-MXSGT group (62.4%) is rather lower than control group (69.6%).than control group (69.6%). Considering the favourable baseline factors, this is more Considering the favourable baseline factors, this is more

48、noted and seriously considered and discussed.noted and seriously considered and discussed. 9. Reported adverse events are extremely few. Its 9. Reported adverse events are extremely few. Its unbelievable.unbelievable. 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 24 In the RCTs of oseltamivir for treatment of season

49、al flu In the RCTs of oseltamivir for treatment of seasonal flu done in the western countries or in Japan, percent of done in the western countries or in Japan, percent of participants who had at least one adverse event were participants who had at least one adverse event were report about 40 to 50

50、%.report about 40 to 50 %. 10. Please refer the papers which were published recently 10. Please refer the papers which were published recently on the systematicon the systematic review on neuraminidase inhibitor especially on review on neuraminidase inhibitor especially on oseltamivir: as bellow:ose

51、ltamivir: as bellow: 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 25 如此全面、詳細(xì)而具體的審稿意見，如此全面、詳細(xì)而具體的審稿意見， 對于作者進(jìn)一步修改稿件，甚至對以后的對于作者進(jìn)一步修改稿件，甚至對以后的 科研選題和設(shè)計，都有極其重要的參考價科研選題和設(shè)計，都有極其重要的參考價 值，是十分寶貴的。即使稿件退稿了，但值，是十分寶貴的。即使稿件退稿了，但 如果作者按照審稿人的意見仔細(xì)修改，稿如果作者按照審稿人的意見仔細(xì)修改，稿 件很有可能被其他期刊錄用、刊登。這樣件很有可能被其他期刊錄用、刊登。這樣 的例子已經(jīng)有不少。的例子已經(jīng)有不少。 國外和國內(nèi)醫(yī)學(xué)期刊的

52、不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 26 組稿的不同組稿的不同主動、積極主動、積極 有些國際期刊的主要負(fù)責(zé)人親自組稿。如有些國際期刊的主要負(fù)責(zé)人親自組稿。如 NEJM總編輯總編輯JF Drazen教授教授在在SARSSARS暴發(fā)后，以暴發(fā)后，以 及某一年我國發(fā)生流腦暴發(fā)后，親自來電話尋求及某一年我國發(fā)生流腦暴發(fā)后，親自來電話尋求 約稿，在全球醫(yī)學(xué)期刊中最早刊登出關(guān)于約稿，在全球醫(yī)學(xué)期刊中最早刊登出關(guān)于SARSSARS的的 學(xué)術(shù)論文。有一次，他出差在酒店看電視，無意學(xué)術(shù)論文。有一次，他出差在酒店看電視，無意 中聽到有新聞講講英國臨床試驗(yàn)造成健康志愿者中聽到有新聞講講英國臨床試驗(yàn)造成健康志愿者

53、危及生命的循環(huán)衰竭，立即與研究人員聯(lián)系約稿，危及生命的循環(huán)衰竭，立即與研究人員聯(lián)系約稿， 刊登出細(xì)胞因子風(fēng)暴的論文，他親自為該文撰寫刊登出細(xì)胞因子風(fēng)暴的論文，他親自為該文撰寫 述評。與大型學(xué)術(shù)會結(jié)合，尋求合適的時機(jī)發(fā)表述評。與大型學(xué)術(shù)會結(jié)合，尋求合適的時機(jī)發(fā)表 文章。文章。 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 27 專家參與期刊工作的程度不同專家參與期刊工作的程度不同 國外期刊高度重視專家參與期刊的工國外期刊高度重視專家參與期刊的工 作，創(chuàng)造極好的條件，使專家將期刊工作作，創(chuàng)造極好的條件，使專家將期刊工作 當(dāng)做自己的工作來作。以當(dāng)做自己的工作來作。以NEJMNEJM為例為

54、例，有，有9名名 Associate editors, 他們都是波士頓地區(qū)，他們都是波士頓地區(qū)， 特別是哈佛大學(xué)醫(yī)學(xué)院的教學(xué)醫(yī)院的學(xué)術(shù)特別是哈佛大學(xué)醫(yī)學(xué)院的教學(xué)醫(yī)院的學(xué)術(shù) 帶頭人，他們基本保證出席每周一次的總帶頭人，他們基本保證出席每周一次的總 編、副總編審稿會，經(jīng)認(rèn)真的討論，決定編、副總編審稿會，經(jīng)認(rèn)真的討論，決定 刊出哪些文章?？瞿男┪恼?。 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 28 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 29 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 30 高度重視網(wǎng)站建設(shè)高度重視網(wǎng)站建設(shè) 注重網(wǎng)站的更新、改版，吸

55、引讀者閱讀，注重網(wǎng)站的更新、改版，吸引讀者閱讀， 提提 高影響力，給讀者提供大量有臨床應(yīng)用價值的音頻、高影響力，給讀者提供大量有臨床應(yīng)用價值的音頻、 視頻等多媒體資料，提高期刊的影響力。如每周一視頻等多媒體資料，提高期刊的影響力。如每周一 次的次的“Audio Briefing”音頻材料，音頻材料，“Video in Clinical Medicine”的視頻材料，的視頻材料，“Clinical Practice”全文錄音材料，等等。另外還提供個體全文錄音材料，等等。另外還提供個體 化的文獻(xiàn)服務(wù)等?？紤]到未來媒體的發(fā)展，盡可能化的文獻(xiàn)服務(wù)等?？紤]到未來媒體的發(fā)展，盡可能 多地提供適合于無線媒體

56、、掌上電腦等設(shè)備的文獻(xiàn)多地提供適合于無線媒體、掌上電腦等設(shè)備的文獻(xiàn) 資料，如資料，如MP3或或MP4等格式的文件資料。等格式的文件資料。 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 31 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 32 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 33 期刊與讀者的互動性強(qiáng)期刊與讀者的互動性強(qiáng) 用多種方式與讀者互動，包括鼓勵刊登用多種方式與讀者互動，包括鼓勵刊登 通訊文章、在網(wǎng)站上邀請讀者參與一些病例通訊文章、在網(wǎng)站上邀請讀者參與一些病例 的診斷或治療方法選擇，以及定期召開與青的診斷或治療方法選擇，以及定期召開與青 年

57、醫(yī)師的座談會等。網(wǎng)站上設(shè)繼續(xù)教育項目，年醫(yī)師的座談會等。網(wǎng)站上設(shè)繼續(xù)教育項目， 提供繼續(xù)教育學(xué)分。提供繼續(xù)教育學(xué)分。 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 34 國際期刊國際期刊對稿件的要求更嚴(yán)格對稿件的要求更嚴(yán)格： 1 1、篇幅相對長、篇幅相對長 2 2、要求方法部分的內(nèi)容更詳細(xì)、具體、要求方法部分的內(nèi)容更詳細(xì)、具體 3 3、對倫理學(xué)和統(tǒng)計學(xué)的要求更高、更嚴(yán)謹(jǐn)、對倫理學(xué)和統(tǒng)計學(xué)的要求更高、更嚴(yán)謹(jǐn) 4 4、對前瞻性臨床試驗(yàn)稿件，要求必須在研究開始、對前瞻性臨床試驗(yàn)稿件，要求必須在研究開始 前在規(guī)定的網(wǎng)站上注冊。前在規(guī)定的網(wǎng)站上注冊。 5 5、要求公開作者的利益沖突或關(guān)系、要

58、求公開作者的利益沖突或關(guān)系 6 6、對參考文獻(xiàn)數(shù)目的限制較松，可引用較多文獻(xiàn)、對參考文獻(xiàn)數(shù)目的限制較松，可引用較多文獻(xiàn) 7 7、綜合性醫(yī)學(xué)期刊要求稿件有普遍影響力、綜合性醫(yī)學(xué)期刊要求稿件有普遍影響力 8 8、許多國際醫(yī)學(xué)期刊對稿件的處理速度快、許多國際醫(yī)學(xué)期刊對稿件的處理速度快 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 35 我國已有我國已有2020多部醫(yī)學(xué)期刊進(jìn)入多部醫(yī)學(xué)期刊進(jìn)入 SCISCI，也有，也有8080多部醫(yī)學(xué)期刊進(jìn)入多部醫(yī)學(xué)期刊進(jìn)入 MedlineMedline。我相信，通過與國際一流。我相信，通過與國際一流 醫(yī)學(xué)期刊的交流與合作，通過學(xué)習(xí)國醫(yī)學(xué)期刊的交流與合作，

59、通過學(xué)習(xí)國 際一流醫(yī)學(xué)期刊辦刊方針、方法等，際一流醫(yī)學(xué)期刊辦刊方針、方法等， 我國醫(yī)學(xué)和其他科技期刊將會取得更我國醫(yī)學(xué)和其他科技期刊將會取得更 多的進(jìn)步和成功多的進(jìn)步和成功! ! 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 36 謝謝 謝謝 ! ! 國外和國內(nèi)醫(yī)學(xué)期刊的不同之處照日格 圖中華醫(yī)學(xué)雜志英文版 37 C&c)3TUqiu5*wKSqB(B3OKWl9z!soSxwNIo*t*mLQSFlXSmE%1!y6BPVixcODA-QhsT!qdvbWKZ4znYpIqVzhY6tKbgLh-k3QLA%e(51e$LT9ujRLu4WrJIu&p#3wNuFQyJCU#eD

60、2eeG71yR#eWbdkV22Ds1Qj4WY5)TCDO+P$*UcghGFRConPhW1T%eM+(nXtiMHLM*ag1!WgXKO$d(v$XOVb8MEs%ymi6wgEW-V!oRUb%6q!8p%x)K&xI+A1cWAR#y-BFpIiq+YpHdYlb)siah3NVI$v!&nsaouN- Pflm(OhTNZtQpUgMtYbI0ivET&%yPd88Cc$xOhvr2b+G#1SRQyx%7vkm%d9dCGSL4W31Nps9!bpVs+8UMK8p-ZQkA6d%bnU7qW6FOGyz1AjQDw(#maYciXFOR6WjLNv#ClK#y!ODI+vL